Salicylic Augmentation in Depression



Status:Recruiting
Conditions:Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 65
Updated:2/20/2019
Start Date:November 15, 2018
End Date:August 2020
Contact:Jessica Harder, MD
Email:jaharder@partners.org
Phone:617-732-6753

Use our guide to learn which trials are right for you!

The investigators are doing this research study to find out if using aspirin along with
antidepressant treatment can lessen symptoms of depression. This study also aims to find out
if some people improve more from taking aspirin than others. The investigators also want to
see if it is possible to predict which participants will do better based on a blood test.

Aspirin is approved by the U.S. Food and Drug Administration (FDA) as an over-the-counter
pain medication. But, aspirin is not approved by the FDA to make antidepressant treatment
better.

This research study will compare aspirin to placebo.

This study is a randomized, double-blind, placebo-control trial. The primary aims of this
study are:

Aim 1: To evaluate the clinical effect of aspirin augmentation on depression.

Aim 2: To assess the inflammatory profile of the blood of the aspirin augmentation responders
compared with the non-responders.

Aim 3: To evaluate whether immune gene expression patterns are associated with antidepressant
response to aspirin.

Aim 4: To collect samples for later, more detailed immunologic characterization.

Inclusion Criteria:

- Current diagnosis of major depressive disorder

- Hamilton Depression Rating Scale (HDRS) score of >19

- Stable treatment regimen (no medication changes or changes in psychotherapy treatment
in past 8 weeks, and no participation in stepped treatments, such as completion of a
course of cognitive behavioral therapy, during the trial)

- Failed to remit with at least 1 antidepressant trial, or combination of 1
antidepressant and 1 augmentation agent

- Women of childbearing age must agree to use an approved method of contraception for
the duration of the study

Exclusion Criteria:

- Active suicidal ideation

- History of manic episodes or psychosis

- Alcohol or substance use disorder up to one month prior to first testing session

- Comorbid neurologic condition affecting the central nervous system

- Comorbid autoimmune condition

- Uncorrected thyroid disease or a current abnormal thyroid-stimulating hormone (TSH)

- Active or recent (within the past month) infection (such as otitis, pneumonia, urinary
tract infection); temperature > 100.3 or white blood cell (WBC) count > 11 K/microL
will be considered evidence of active infection even in the absence of other symptoms

- History of GI bleed

- History of stroke

- History of a bleeding disorder

- Platelet count < 150,000/mm3 on initial screening

- On a blood-thinning agent or taking NSAIDs daily

- Current use of oral steroids or other immunomodulating medications

- Salicylate sensitivity

- Pregnancy or breastfeeding
We found this trial at
1
site
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Jessica Harder, MD
Phone: 617-732-6753
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials